aTyr Pivots Efzofitimod to a Niche Sarcoidosis Subgroup on Post-Hoc Data

aTyr Pharma Presents Positive Efzofitimod Subgroup Data in Pulmonary Sarcoidosis

aTyr Pharma announced it will present a subgroup analysis from its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis at the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) 2026 Congress. The analysis focused on 44 patients with restrictive lung disease, demonstrating that efzofitimod (5.0 mg/kg arm) led to a clinically meaningful benefit in lung function, with a placebo-adjusted week 48 change from baseline for FVC of 123.8 ml, and positive trends in multiple patient-reported outcomes. The company has submitted a protocol to the FDA for a planned Phase 3 study in this specific patient population, utilizing FVC as the primary endpoint.

• The post hoc analysis of the EFZO-FIT™ study, focusing on 44 patients with prespecified restrictive lung disease (FVCpp ≤ 80%, FEV1/FVC ≥ 0.7), showed that the 5.0 mg/kg efzofitimod arm achieved a placebo-adjusted week 48 change from baseline in FVC of 123.8 ml. Additionally, improvements were observed in patient-reported outcomes including KSQ-Lung, KSQ-General Health, Fatigue Assessment Scale, and Leicester Cough Questionnaire, alongside similar steroid reduction to placebo.
• Following interactions with the U.S. Food and Drug Administration (FDA), aTyr Pharma submitted a protocol in June 2026 for a new planned Phase 3 study of efzofitimod. This study will specifically target patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, with Forced Vital Capacity (FVC) as the primary endpoint and King’s Sarcoidosis Questionnaire (KSQ)-Lung score as the key secondary endpoint.
• Efzofitimod is a novel biologic immunomodulator derived from tRNA synthetase, designed to selectively modulate activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression. It is currently in clinical development for interstitial lung disease (ILD), including pulmonary sarcoidosis, where existing treatments often have limited efficacy and significant side effects, highlighting a critical unmet medical need.

Planned Phase 3 Study Design for Efzofitimod in Restrictive Lung Disease

Clinical trial designs for pulmonary sarcoidosis have evolved significantly, shifting from a primary reliance on radiological changes toward more comprehensive, patient-centric endpoints. Recent studies and consensus guidelines prioritize outcomes such as corticosteroid-sparing effects, objective improvements in pulmonary function, and patient-reported quality of life. The following table summarizes key design parameters from notable historical and contemporary trials that illustrate this progression.

Addressing Unmet Needs in Restrictive Pulmonary Sarcoidosis

Despite decades of clinical experience, pulmonary sarcoidosis remains without a dedicated FDA-approved therapy beyond prednisone and repository corticotropin injection, and management continues to be guided largely by low-quality evidence in the absence of a standardized treatment paradigm. This gap is compounded by an incomplete understanding of disease pathogenesis, marked inter-patient variability in treatment response, and a persistent lack of validated predictive biomarkers. Diagnostic delay (mean 7.93 months) and heterogeneous clinical presentation further complicate both individual patient management and the design of robust drug trials, while relapse rates ranging from 13% to 75% underscore the absence of consensus on disease activity monitoring. Recent progress includes the PREDMETH trial establishing methotrexate as noninferior to prednisone as first-line therapy—signaling a "less is more" shift away from prolonged high-dose steroids—alongside early biomarker work (e.g., EV Serpin C1, PD-1+ T-cell subsets) and a Delphi-based expert consensus on clinical trial endpoints spanning steroid-sparing, lung function, and quality-of-life domains.

Target populations for emerging interventions are increasingly well-defined. These include the 10–40% of patients who progress to advanced pulmonary disease, particularly the subset reaching Stage IV fibrocystic disease with >20% fibrosis on HRCT or pre-capillary pulmonary hypertension, who face over 40% five-year mortality; up to 70% of these patients may develop precapillary pulmonary hypertension and could benefit from PAH-targeted therapies. Refractory patients unable to taper corticosteroids, or those with unacceptable steroid toxicity, represent a priority group for corticosteroid-sparing regimens, including immunosuppressants (methotrexate, azathioprine), anti-TNF agents, and emerging biologics. Investigational approaches under active exploration include JAK inhibitors (tofacitinib), mTOR inhibitors, efzofitimod (a neuropilin-2 inhibitor showing promise in pilot pulmonary studies), antifibrotics such as nintedanib, and transcriptome-guided repositioning candidates like infliximab, alongside CTLA-4, IL-6, NLRP3 inflammasome, GM-CSF, and PDE-4 inhibitors. Demographically, disease burden and unmet need concentrate in adults aged 70–84 (with peak incidence at 70–74 and peak prevalence at 85–89), males over 60, and younger patients (18–44) hospitalized with sarcoidosis-associated pulmonary embolism—particularly young Black patients with elevated comorbidity burden (obesity, smoking, prior VTE)—who show significantly higher mortality risk.

Beyond therapeutics, structural and epidemiological challenges shape the unmet need landscape. Marked disparities by geography, age, and sociodemographic index persist, with the highest burden in high-SDI regions such as Andean Latin America and High-income Asia Pacific; global projections anticipate an 83.5% rise in crude death rates and a 60.4% rise in DALYs by 2050, driven primarily by population aging rather than rising standardized incidence. This trajectory underscores the need for equitable healthcare resource allocation, biomarker-guided surveillance, and integration of multidisciplinary, combined rheumatology-pulmonary care models—especially for patients with multi-organ involvement (65.3% of clinic populations) and cardiac or neurologic manifestations. Patient-reported priorities reinforce these clinical imperatives: in a survey of over 1,000 US sarcoidosis patients, fear of disease progression, organ spread, and lack of improvement ranked above concerns about health-related quality of life, highlighting disease progression control as the central unmet need driving current drug development and trial design.